Slovenia

Please select...

Disclosure of payments made to HCPs and HCOs in Slovenia

In recent years GSK has challenged the traditional commercial model of pharmaceutical companies with industry-leading improvements to how we do business. Our improvements aim to meet society’s growing expectation for organisations and individuals to act with transparency. This includes relationships between our industry and healthcare professionals (HCPs) or healthcare organisations (HCOs) so all of these interactions are conducted with integrity and transparency.

We fully support the European Federation of Pharmaceutical Industries and Associations (EFPIA) Code on the disclosure of individual transfers of value from pharmaceutical companies to healthcare professionals and healthcare organisations.

Since the beginning of 2016, GSK ended payments to healthcare professionals to speak in our events about our prescription medicines or vaccines to audiences who prescribe or influence prescribing. At the same time GSK stopped providing financial support directly to individual HCPs to attend medical congresses.  In addition, in Slovenia we have previously implemented guidance from the Slovene Commission for the Prevention of Corruption and provide support for HCPs to attend congresses only through support given to HCPs’ employers such as hospitals, healthcare centres based on unsolicited requests, filled in (or received) via a transparent template published on our website.

These changes go further than the current industry codes and therefore others in the industry. We continue to work with HCPs for non-promotional activities such as clinical research.

These changes at GSK are global and go further than the current industry codes. We want to reduce a potential perception among patients that they might be prescribed a medicine for any other reason than what it is right for their condition.

Collaboration with HCPs and HCOs continues to be important. GSK collaborates with HCPs and HCOs for non-promotional activities such as clinical research. We have also introduced new ways of delivering information to HCPs, introducing digital and real-time applications to improve delivery of medical information.

Under the EFPIA Code, the first disclosures – of payments made during 2015 – were made by 30 June 2016: these were disclosed transfers of value made in 2015 to HCPs and HCOs in connection with prescription medicines on an individual-named basis (aggregate by exception only). We are following the same process for disclosures of 2016 data of which all disclosures must be made by 30 June 2017.

We believe these disclosures will help create a better understanding of how the pharmaceutical industry works with HCPs and HCOs. Given the measures GSK has put in place we seek to increase confidence in, and understanding of, how and why we work with healthcare professions for the sustainable improvement of healthcare and in the best interests of patients. More information on our approach to the EFPIA code, how we are leading improvements to industry practices, and the importance of our partnerships with HCPs and HCOs can be found below, and is set out in greater detail.

Our disclosures for Slovenia

The links below will take you to our disclosures for Slovenia in line with the EFPIA code and Forum of International Research & Development Pharmaceutical companies (EIG), and to a note on the methodology used to set out the data in the report.

Year

Report

Methodological Note

Infographic

2016 PDF PDF PDF
Previous year(s) 
2015 PDF PDF N/A

Media enquiries: For more information please contact Alja Plevnik Kapun at: alja.k.plevnik@gsk.com

Our approach to implementing the EFPIA Code and HCP payments

Since 1 January 2016, we ended in all parts of the world any payments to external HCPs to speak about our prescription medicines and vaccines although payments before this date are reflected in the 2015 disclosures. For work with external HCPs, which now entails non-promotional activities only, we have applied a “no disclosure consent, no contract” policy to enable and drive disclosure at an individual level and therefore fulfil our commitment to the EFPIA code. This means:

  • Where individual-named disclosure is required under the EFPIA Disclosure Code we will actively seek the necessary consent from each HCP with whom we work.
  • We will not work with HCPs where consent is not given. Where consent is given but subsequently withdrawn we will not then work with that HCP on activities covered by individual disclosure for a period of one year.

We will continue to work with HCPs for non-promotional activities including conducting clinical research and seeking advice on clinical relevance and appropriate communication of the results of our research, as well as identifying new research areas, as these interactions are an essential part of how we ensure medicines we develop meet patients’ needs.

Find out how disclosing information on payments to doctors has already had positive effects in Europe.

We also continue to work towards publishing global figures at an aggregate level for payments to HCPs, for activities such as advisory services and clinical research. In many countries outside Europe we already publish payments to HCPs – for example, in Australia, Japan and the US. Find out more about our payments to HCPs in the USA, Europe and the rest of the world on the other pages within this section. We will continue to support and work towards increased transparency in other countries as industry associations and/or governments establish specific guidelines for disclosure.

 

Objava plačil zdravstvenim delavcem in zdravstvenim organizacijam v Sloveniji

V zadnjih letih je družba GSK spremenila tradicionalni poslovni model farmacevtskih družb in je v svoje poslovanje uvedla spremembe, ki so v industriji vodilne. Cilj teh izboljšav je izpolniti naraščajoče družbeno pričakovanje, da naj bo delovanje organizacij in posameznikov pregledno. To velja tudi za odnose med našo industrijo in zdravstvenimi delavci ali zdravstvenimi organizacijami, da bodo vsi stiki potekali z integriteto in pregledno.

V celoti podpiramo kodeks evropskega združenja farmacevtske industrije EFPIA (European Federation of Pharmaceutical Industries and Associations) o objavi posameznih nakazil, ki jih farmacevtske družbe izvedejo zdravstvenim delavcem in zdravstvenim organizacijam.

Od začetka leta 2016 družba GSK zdravstvenim delavcem ne plačuje več za predavanja na naših dogodkih o naših zdravilih na recept in cepivih pred publiko, ki lahko zdravila predpisuje ali vpliva na njihovo predpisovanje. Obenem s tem je družba GSK prenehala dajati finančno podporo za udeležbo na medicinskih kongresih neposredno zdravstvenim delavcem.

V Sloveniji smo poleg tega že prej udejanili smernice slovenske Komisije za preprečevanje korupcije ter smo podporo zdravstvenim delavcem za udeležbo na kongresih izvajali le preko njihovega delodajalca, na primer bolnišnice ali zdravstvenega doma, na podlagi nespodbujanih prošenj, vloženih (ali prejetih) preko transparentne predloge, objavljene na našem spletnem mestu.

Te spremembe gredo dlje od veljavnih kodeksov v industriji in s tem tudi dlje od drugih udeležencev v naši industriji. Z zdravstvenimi delavci še naprej sodelujemo pri nepromocijskih dejavnostih, kot so klinične raziskave.

Te spremembe v družbi GSK so globalne in gredo dlje od veljavnih kodeksov v industriji. Zmanjšati namreč želimo možnost, da bi imeli bolniki vtis, da so zdravilo morda dobili zaradi kakršnega koli drugega razloga kot zaradi utemeljenega vzroka, povezanega s svojo boleznijo.

Sodelovanje z zdravstvenimi delavci in zdravstvenimi organizacijami še naprej ostaja pomembno. Družba GSK z enimi in drugimi sodeluje pri nepromocijskih dejavnostih, kot so klinične raziskave. Uvedli smo tudi nove načine posredovanja informacij zdravstvenim delavcem z uvedbo digitalnih aplikacij v realnem času za izboljšanje razširjanja medicinskih informacij.

V skladu s kodeksom EFPIA so bila prva objava – tj. objava o plačilih, izvedenih v letu 2015 – opravljena 30. junija 2016: to so bile objave prenosov vrednosti, izvedenih leta 2015 zdravstvenim delavcem in zdravstvenim organizacijam v zvezi z zdravili na recept, in sicer z individualnim poimenovanjem (le izjemoma agregirano). Enakemu postopku sledimo pri objavi podatkov za leto 2016, ki mora biti v celoti izvedeno do 30. junija 2017.

Prepričani smo, da bodo te objave pripomogle k boljšemu razumevanju sodelovanja med farmacevtsko industrijo ter zdravstvenimi delavci in zdravstvenimi organizacijami. Z ukrepi, ki smo jih je uresničili v družbi GSK, poskušamo povečati zaupanje in razumevanje tega, kako in zakaj sodelujemo z zdravstvenimi delavci, za trajnostno izboljševanje zdravstvenega varstva in v najboljšem interesu bolnikov. Več informacij o našem pristopu h kodeksu EFPIA, naši vodilni vlogi pri izboljšanju prakse v industriji in o pomenu našega partnerstva z zdravstvenimi delavci in zdravstvenimi organizacijami lahko najdete v nadaljevanju, podrobneje pa so predstavljene tukaj.

Naše objave za Slovenijo

Preko spodnjih povezav pridete do naših objav za Slovenijo v skladu s kodeksom EFPIA in Mednarodnega foruma znanstvenoraziskovalnih farmacevtskih družb (GIZ); tam boste našli tudi opombo o metodologiji, uporabljeni za pripravo podatkov v poročilu.

Leto

Poročilo

Metodološka opomba

Infografika

2016 PDF PDF PDF
Prejšnje leto/
prejšnja leta
2015 PDF PDF N/A

Poizvedbe medijev:
Za več informacij se obrnite na Aljo Plevnik Kapun na naslov: alja.k.plevnik@gsk.com

Naš pristop k udejanjanju kodeksa EFPIA in k plačilom zdravstvenim delavcem

S 1. januarjem 2016 smo po vsem svetu prenehali plačevati zunanjim zdravstvenim delavcem za predavanja o naših zdravilih na recept in cepivih; plačila pred tem datumom so še prikazana v objavah za leto 2015. Sodelovanje z zunanjimi zdravstvenimi delavci zdaj obsega le nepromocijske dejavnosti in zanj smo uveljavili politiko "brez soglasja za objavo ni pogodbe"; to nam omogoča objave na ravni posameznika in s tem izpolnitev obveznosti po kodeksu EFPIA. To pomeni:

  • V primerih, ko kodeks EFPIA o objavi zahteva objavo na ravni posameznika, si bomo dejavno prizadevali pridobiti potrebno soglasje od vsakega zdravstvenega delavca, s katerim sodelujemo.
  • Z zdravstvenimi delavci, ki takšnega soglasja ne bodo dali, ne bomo sodelovali. Če zdravstveni delavec poda soglasje, a ga pozneje umakne, z njim v obdobju enega leta ne bomo več sodelovali pri dejavnostih, ki jih zajema objava na ravni posameznika.

Še naprej bomo z zdravstvenimi delavci sodelovali pri nepromocijskih dejavnostih, vključno s kliničnimi raziskavami in svetovanjem o kliničnem pomenu in ustreznem komuniciranju rezultatov naših raziskav ter prepoznavanju novih raziskovalnih področij, saj so vse te interakcije nujen sestavni del našega zagotavljanja zdravil, ki jih razvijamo, da bi izpolnili potrebe bolnikov.

Preberite o tem, kako objavljanje informacij o plačilih zdravnikom že prinaša pozitivne učinke v Evropi.

Nadaljujemo tudi objavljanje globalnih podatkov na agregatni ravni o plačilih zdravnikom za dejavnosti, kot so svetovalne storitve in klinične raziskave. V številnih državah zunaj Evrope že objavljamo plačila zdravstvenim delavcem – na primer v Avstraliji, na Japonskem in v ZDA. Na drugih straneh v tem delu lahko najdete več informacij o plačilih zdravstvenim delavcem v ZDA, Evropi in drugod po svetu. Prizadevanja za večjo preglednost bomo še naprej podpirali tudi v drugih državah, kot bodo industrijska združenja in/ali vlade oblikovale specifične smernice za objavo.

Back to top